Consensus Axsome Therapeutics, Inc.

Stocks

AXSM

US05464T1043

Pharmaceuticals

Market Closed - Nasdaq 06:00:00 26/09/26 am AEST			5-day change	1st Jan Change
195.09 ^USD	-0.48%		-6.11%	+6.82%

19/09	Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says	MT
17/09	Axsome Therapeutics, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-16-2026 10:00 AM

Evolution of the Average Target: Axsome Therapeutics, Inc.

Evolution of the Target Price: Axsome Therapeutics, Inc.

Changes in Analyst Recommendations: Axsome Therapeutics, Inc.

b4e6df1be888.a33Pa_-nN2YpnqayRNwxpweg-OCfA_YoDhZu5DxbaWQ.GiLiPMjyYQhnqNaEFoMH_0PatbLOMcB-USEGp3EoPSsKKf8Clp5HPn_r8w~73de531b8ea0b9f565a35368ab1165e2

Analysts' recommendations: Axsome Therapeutics, Inc.

26/09	Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says	MT
23/09	Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating	MT
19/09	Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says	MT
02/09	Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says	MT
12/08	UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating	MT
12/08	Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating	MT
12/08	Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says	MT
11/08	Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating	MT
11/08	RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating	MT
31/07	Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating	MT
21/07	BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target	MT
07/07	RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating	MT
28/05	Axsome Sees Auvelity Momentum, Alzheimer's Agitation Approval Driving Growth Outlook, Oppenheimer Says	MT
05/05	B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating	MT
05/05	Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating	MT
05/05	RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating	MT
04/05	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
04/05	Deutsche Bank Adjusts Axsome Therapeutics PT to $281 From $245, Maintains Buy Rating	MT
30/04	Mizuho Keeps Price Target on Axsome Therapeutics to $228, Maintains Outperform Rating	MT
30/04	Mizuho Adjusts Price Target on Axsome Therapeutics to $228 From $230, Maintains Outperform Rating	MT
29/04	Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating	MT
22/04	Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says	MT
11/04	Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says	MT
10/04	UBS Adjusts Axsome Therapeutics Price Target to $259 From $251, Maintains Buy Rating	MT
07/04	RBC Capital Adjusts Price Target on Axsome Therapeutics to $221 From $222, Maintains Outperform Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AXSOME THERAPEUTICS, INC.					+46.2%
	REGENERON PHARMACEUTICALS, INC.					+7.97%
	MODERNA, INC.					-39.89%
	CSL LIMITED					+1.62%
	SAMSUNG BIOLOGICS CO.,LTD.					+44.41%
	UCB					+32.93%
	BIOGEN INC.					+4.65%
	INCYTE CORPORATION					+3.11%
	INNOVENT BIOLOGICS, INC.					+29.52%
	SWEDISH ORPHAN BIOVITRUM AB					+14.84%
	Average					+14.54%
	Weighted average by Cap.					+6.58%